In response to the US Department of Education's push for stricter oversight of college programs, the DOE and FDA are forming an interagency working group to create unified guidance on foreign drug import policies. This initiative aims to bridge the regulatory void that has emerged, as the FDA has refrained from issuing guidelines, leading to potential compliance conflicts for academic health programs. With a draft framework expected in six months, the collaboration seeks to ensure a coherent regulatory environment amidst growing pressures on higher education institutions.
